EKF Diagnostics Holdings plc

As of December 31, 2025, EKF Diagnostics Holdings plc carries a market capitalization of 11.45B, placing it among publicly traded companies globally. Its enterprise value stands at 10.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

EKF Diagnostics Holdings plc's next confirmed earnings release is scheduled for March 30, 2027.

As of December 31, 2025, EKF Diagnostics Holdings plc has 433.83M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, EKF Diagnostics Holdings plc maintains a current ratio of 4.16, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, EKF Diagnostics Holdings plc's stock has declined approximately 10.33% over the past 52 weeks. The 50-day moving average sits at 25.05, while the 200-day moving average is 25.56.

As of December 31, 2025, EKF Diagnostics Holdings plc holds 1.37B in cash and equivalents against 138.50M in total debt, resulting in a net debt position of -1.37B. Total book value stands at 6.91B, with working capital of 2.35B providing operational flexibility.